The Business Research Company’s report on the Hereditary Angioedema Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the hereditary angioedema market in recent years?
The growing prevalence of rare diseases is expected to propel the growth of the hereditary angioedema market going forward. Rare diseases, also known as orphan diseases, refer to medical conditions that affect a small percentage of the population. The increasing prevalence of rare diseases is due to multiple factors, such as progress in medical research, changes in population demographics, and environmental impacts. Hereditary angioedema (HAE) is a significant rare disease, highlighting the need for specialized treatments and awareness due to its life-threatening swelling episodes. Its rarity and genetic nature make early diagnosis and targeted therapies essential for effective management and improved patient outcomes. For instance, in June 2022, according to Rare Disease Advisor, a US-based online resource company that provides healthcare professionals, hereditary angioedema (HAE) affects approximately 1 in 50,000 individuals, with prevalence estimates ranging from 1 in 10,000 to 1 in 150,000. In the United States, HAE episodes result in approximately 15,000 to 30,000 emergency room visits each year. Therefore, the growing prevalence of rare diseases is driving the growth of the hereditary angioedema market.
Access Your Free Sample of the Global Hereditary Angioedema Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp
What is the projected market size of the hereditary angioedema industry, and how is it expected to grow?
The hereditary angioedema market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.84 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the increasing prevalence of hereditary angioedema, increasing investment in research and development activities, increasing numbers of drug approvals, rising product approval, and rising disposable income.
The hereditary angioedema market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to the growing prevalence of rare diseases, increasing medical expenditure, increasing support from non-profit organizations, increasing awareness of hereditary angioedema, and rising awareness about earlier diagnoses. Major trends in the forecast period include technological advancements, the development of novel therapies, the launch of new drugs, advanced diagnostic tools, and advancements in genetic testing.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22002&type=smp
Who are the key players driving competition in the hereditary angioedema market?
Major companies operating in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc.
What key trends are expected to drive the hepatorenal syndrome market during the forecast period?
Major companies operating in the hereditary angioedema market are developing innovative products, such as oral plasma kallikrein inhibitors, to provide more convenient and effective on-demand treatment options for patients. Oral plasma kallikrein inhibitors are drugs that block plasma kallikrein to prevent excessive bradykinin production, primarily used for treating hereditary angioedema. For instance, in September 2024, KalVista Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the FDA has accepted its new drug application (NDA) for sebetralstat. This investigational oral plasma kallikrein inhibitor is intended for the on-demand treatment of hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and older. Sebetralstat provides a new treatment approach by targeting and inhibiting plasma kallikrein activity. The acceptance of the NDA represents a major milestone toward potential approval and commercialization.
Which key geographies are driving the growth of the hereditary angioedema market?
North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report
What are the key segments driving growth in the hereditary angioedema market?
The hereditary angioedema market covered in this report is segmented –
1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II
2) By Treatment Type: Prophylaxis, On-demand
3) By Drug Class: C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes
4) By Route Of Administration: Subcutaneous, Intravenous, Oral
5) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency, Low C1-Inhibitor Levels, Reduced C1-Inhibitor Function
2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, Genetic Mutations In SERPING1 Gene
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22002
How is the hereditary angioedema market defined?
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in the skin, gastrointestinal tract, and airways due to C1 esterase inhibitor deficiency or dysfunction. It is caused by genetic mutations affecting the complement system, leading to excessive bradykinin production. HAE can be life-threatening if airway swelling occurs, requiring prompt treatment with C1 inhibitor replacement or bradykinin-targeted therapies.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
